- Home
- TYGO vs SRZN Comparison
TYGO vs SRZN Comparison
Compare TYGO & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYGO
- SRZN
- Stock Information
- Founded
- TYGO 2007
- SRZN 2015
- Country
- TYGO United States
- SRZN United States
- Employees
- TYGO N/A
- SRZN N/A
- Industry
- TYGO Semiconductors
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- TYGO Technology
- SRZN Health Care
- Exchange
- TYGO Nasdaq
- SRZN Nasdaq
- Market Cap
- TYGO 82.5M
- SRZN 97.3M
- IPO Year
- TYGO N/A
- SRZN N/A
- Fundamental
- Price
- TYGO $1.72
- SRZN $11.45
- Analyst Decision
- TYGO Strong Buy
- SRZN Strong Buy
- Analyst Count
- TYGO 1
- SRZN 2
- Target Price
- TYGO $6.00
- SRZN $38.50
- AVG Volume (30 Days)
- TYGO 316.8K
- SRZN 12.2K
- Earning Date
- TYGO 11-05-2025
- SRZN 11-05-2025
- Dividend Yield
- TYGO N/A
- SRZN N/A
- EPS Growth
- TYGO N/A
- SRZN N/A
- EPS
- TYGO N/A
- SRZN N/A
- Revenue
- TYGO $74,405,000.00
- SRZN $12,621,000.00
- Revenue This Year
- TYGO $94.76
- SRZN N/A
- Revenue Next Year
- TYGO $19.11
- SRZN N/A
- P/E Ratio
- TYGO N/A
- SRZN N/A
- Revenue Growth
- TYGO 52.31
- SRZN N/A
- 52 Week Low
- TYGO $0.58
- SRZN $5.90
- 52 Week High
- TYGO $1.80
- SRZN $18.17
- Technical
- Relative Strength Index (RSI)
- TYGO 73.82
- SRZN 52.78
- Support Level
- TYGO $1.34
- SRZN $11.36
- Resistance Level
- TYGO $1.45
- SRZN $12.11
- Average True Range (ATR)
- TYGO 0.11
- SRZN 0.69
- MACD
- TYGO 0.04
- SRZN -0.13
- Stochastic Oscillator
- TYGO 89.29
- SRZN 27.07
About TYGO Tigo Energy Inc.
Tigo Energy Inc designs solar power conversion and storage products that provide customers with more choice and flexibility. Its mission is to deliver smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Geographically the company generates revenue from EMEA, Americas, and APAC.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).